Re: 파킨슨 병 .. 안구운동장애, 색맹, 환시 --＞ 자세불안정 증상의 이해.. 2015년 논문...

[문형철]

J Parkinsons Dis. 2015; 5(4): 715–726.

Published online 2015 Nov 24. doi: 10.3233/JPD-150686

PMCID: PMC4927837

PMID: 26599301

Oculo-Visual Dysfunction in Parkinson’s Disease

R.A. Armstrong*

Author information Copyright and License information PMC Disclaimer

Go to:

Abstract

This review describes the oculo-visual problems likely to be encountered in Parkinson’s disease (PD) with special reference to three questions:

(1) are there visual symptoms characteristic of the prodromal phase of PD,

(2) is PD dementia associated with specific visual changes, and

(3) can visual symptoms help in the differential diagnosis of the parkinsonian syndromes, viz.

PD, progressive supranuclear palsy (PSP), dementia with Lewy bodies (DLB), multiple system atrophy (MSA), and corticobasal degeneration (CBD)? Oculo-visual dysfunction in PD can involve visual acuity, dynamic contrast sensitivity, colour discrimination, pupil reactivity, eye movement, motion perception, and visual processing speeds. In addition, disturbance of visuo-spatial orientation, facial recognition problems, and chronic visual hallucinations may be present. Prodromal features of PD may include autonomic system dysfunction potentially affecting pupil reactivity, abnormal colour vision, abnormal stereopsis associated with postural instability, defects in smooth pursuit eye movements, and deficits in visuo-motor adaptation, especially when accompanied by idiopathic rapid eye movement (REM) sleep behaviour disorder. PD dementia is associated with the exacerbation of many oculo-visual problems but those involving eye movements, visuo-spatial function, and visual hallucinations are most characteristic. Useful diagnostic features in differentiating the parkinsonian symptoms are the presence of visual hallucinations, visuo-spatial problems, and variation in saccadic eye movement dysfunction.

이 리뷰에서는 

(1) 파킨슨병 전구기에 특징적인 시각 증상이 있는지, 

(2) 파킨슨병 치매는 특정 시각 변화와 관련이 있는지, 

(3) 시각 증상이 파킨슨 증후군 감별 진단에 도움이 되는지 등 

세 가지 질문을 중심으로 파킨슨병(PD)에서 발생할 수 있는 

안구 시각 문제에 대해 설명합니다.

 PD, 

진행성 핵상 마비(PSP), 

루이소체 치매(DLB), 

다계통 위축(MSA), 

피질 기저부 퇴행(CBD)? 

PD의 안구 시각 기능 장애에는 

시력, 동적 대비 감도, 색 구분, 동공 반응성, 안구 운동, 동작 지각, 시각 처리 속도 등이 포함될 수 있습니다. 

PD, progressive supranuclear palsy (PSP), dementia with Lewy bodies (DLB), multiple system atrophy (MSA), and corticobasal degeneration (CBD)? Oculo-visual dysfunction in PD can involve visual acuity, dynamic contrast sensitivity, colour discrimination, pupil reactivity, eye movement, motion perception, and visual processing speeds

또한 

시공간 방향 감각 장애, 

얼굴 인식 문제, 

만성적인 시각 환각이 나타날 수 있습니다. 

disturbance of visuo-spatial orientation, facial recognition problems, and chronic visual hallucinations

PD의 전구 증상으로는 

동공 반응성에 영향을 미칠 수 있는 

자율신경계 기능 장애, 

색각 이상, 

자세 불안정성과 관련된 비정상적인 입체시, 

원활한 안구 운동의 결함, 

특히 특발성 급속 안구 운동(REM) 수면 행동 장애가 동반되는 경우 

시각 운동 적응의 결함 등이 있을 수 있습니다. 

PD 치매는 

여러 안구 시각 문제의 악화와 관련이 있지만 

안구 운동, 

시공간 기능, 

시각 환각과 관련된 문제가 가장 특징적입니다. 

파킨슨병 증상을 감별하는 데 유용한 진단적 특징은 

시각 환각, 

시각 공간 문제, 

saccadic 안구 운동 기능 장애의 변화입니다.

visual hallucinations,

visuo-spatial problems, and

variation in saccadic eye movement dysfunction.

https://clinicalmovementdisorders.biomedcentral.com/articles/10.1186/s40734-015-0025-4

안진 운동은 시각적으로 관심 있는 물체로 초점을 이동시키기 위해 고안된 빠른 안구 운동입니다. 안진 운동의 이상은 여러 운동 장애를 진단하는 데 중요한 단서를 제공합니다. 이 리뷰에서는 수평 및 수직 안진의 해부학적 구조를 살펴보고, 안진 검사의 실제적인 측면에 대해 논의하며, 고전적인 사례의 비디오 데모를 통해 과운동 및 저운동 운동 장애에서 안진 이상이 진단에 어떻게 도움이 되는지 검토합니다. 사경 시작의 용이성, 사경의 운동 범위 및 접합성, 사경의 속도와 정확성, 동적 사경 궤적, 사경 침입 및 진동의 유무에 대한 기록은 이 검사의 중요한 구성 요소입니다. 또한 운동 장애 환자의 감별 진단에서 사카이드의 가치를 입증할 수 있는 실용적인 알고리즘을 제공합니다.

Keywords: Parkinson’s disease (PD), oculo-visual dysfunction, prodromal phase, PD dementia, Parkinsonian syndromes, differential diagnosis

INTRODUCTION

Patients with Parkinson’s disease (PD) can exhibit significant non-motor symptoms including apathy [1], depression, sleep problems, cognitive impairment, dementia, and autonomic, gastrointestinal, and sensory dysfunction [2]. Sensory problems may include oculo-visual dysfunction, loss of smell, auditory problems, and ‘restless legs’ syndrome [3]. A variety of oculo-visual problems have been reported in PD including defects in primary vision such as visual acuity (VA), colour vision, and eye movement, and deficits in more complex visual tasks involving the ability to judge distance or the shape of an object [2, 4]. Visual deficits in PD are important in influencing overall motor function [5], are a risk factor for developing hallucinations [6], and can have a significant influence on general quality of life [2].

There is increasing recognition of a prodromal phase which may precede actual diagnosis of PD by several years and which could involve non-dopamine as well as dopamine-related pathways [7]. In addition, the concept of ‘Parkinson’s disease associated risk syndrome’ has been proposed in which at risk patients may possess genetic factors which predispose to the disease or exhibit early non-motor risk symptoms [8]. Hence, motor features, autonomic system dysfunction, and neuropsychological disturbances may occur early in PD [7, 9, 10]. Some of these changes may reflect degeneration of the central and peripheral dopamine neurotransmitter systems, early in the disease [11]; the delay between onset of dopamine denervation and the appearance of motor symptoms being 5–20 years [7]. It may be possible to identify potential biomarkers that can detect individuals at an early stage of PD thus permitting early intervention and potential neuroprotection [10]. Strictly, prodromal disease defines a condition that exists before PD is definitely diagnosed, and hence studies of early clinical PD are not directly assessing prodromal disease, although such features may ultimately be shown to be present in the prodromal phase [12].

Cognitive disturbance can also occur in PD as the disease develops and can vary from subtle mental dysfunction to overt dementia [13]. Dementia associated with PD (PD dementia) is a particularly debilitating condition, 80% of patients being potentially at risk [14]. The risk of PD dementia increases with patient age, 90% of recorded cases being over 70 years of age [15]. In a longitudinal, community-based study of patients with newly diagnosed PD, 10% of patients developed dementia at a mean of 3.5 years after diagnosis and 57% showed evidence of cognitive impairment, fronto-striatal deficits being the most common [16]. The most important predictors of dementia were tests of semantic fluency and copying geometric figures, tasks which are affected by posterior cortical pathology, and probably associated with non-dopamine dysfunction [16]. Gray matter atrophy in PD varies with the extent of cognitive impairment [17]. Hence, PD patients with little cognitive impairment exhibit no significant differences in atrophy compared with the cognitively unimpaired. By contrast, PD patients with mild cognitive impairment exhibit limited atrophy affecting temporal, parietal, and frontal cortices as well as the caudate nucleus, hippocampus, amygdala, and putamen. In PD dementia, reduced gray matter volume in the parahippocampal gyrus, visual cortex, and cingulate gyrus may be additionally present [17]. Recently, the presence of olfactory deficits in PD has been linked to an increased risk of developing PD dementia [14] although this remains a controversial finding [18].

PD is also a member of a larger group of closely-related motor disorders, viz. the ‘parkinsonian syndromes’. This group includes progressive supranuclear palsy (PSP) [19], dementia with Lewy bodies (DLB) [20], multiple system atrophy (MSA) [21], and corticobasal degeneration (CBD) [22]. Differential diagnosis of PD within this group can be difficult, especially early in the disease, but where visual signs and symptoms are present they may be useful adjuncts to diagnosis [2].

This article reviews the oculo-visual symptomology of PD with special reference to three questions: (1) are there visual symptoms characteristic of the prodromal phase of the disease, (2) is PD dementia associated with an exacerbation of specific visual changes, and (3) can visual symptoms aid the differential diagnosis of the parkinsonian syndromes? The molecular and neurotransmitter deficits which may be responsible for many of these visual changes are also discussed.

소개

파킨슨병(PD) 환자는

무관심[1], 우울증, 수면 장애, 인지 장애, 치매, 자율신경계, 위장 및 감각 기능 장애 등

심각한 비운동 증상을 보일 수 있습니다[2].

감각 문제에는

안구 시각 기능 장애,

후각 상실,

청각 문제,

하지 불안 증후군[3]이 포함될 수 있습니다.

파킨슨병(PD)은 기저핵 기능 장애의 징후로서 음성 변조 및 음성 출력 감소를 비롯한 여러 가지 언어 장애와 관련이 있습니다. 흥미롭게도 이전 연구에 따르면 PD를 가진 참가자는 음성 생성 중 예기치 않은 기본 주파수 교란에 대한 피드백 기반 운동 반응이 증가하고, 대조군 참가자에 비해 보컬 피치의 차이를 감지하는 능력이 향상되는 것으로 나타났습니다. 여기에서는 이러한 향상된 반응의 한 가지 가능한 원인을 살펴보았습니다. 우리는 PD와 대조군 참가자의 음성 음절 [da]의 반복에 대한 주파수 추종 청성 뇌간 반응(FFR)을 기록했습니다. PD 참가자는 대조군에 비해 음성 자극의 기본 주파수와 관련된 더 큰 진폭의 FFR을 보였습니다. 현재의 예비 결과는 PD에서 기저핵의 기능 장애가 청각 처리의 초기 단계에 기여하며 이 질환과 관련된 광범위한 감각 운동 처리 장애의 한 구성 요소를 반영할 수 있음을 시사합니다.

시력(VA),

색각,

안구 운동과 같은 일차 시력의 결함,

거리나 물체의 모양을 판단하는 능력과 관련된 보다 복잡한 시각 작업의 결함 등

다양한 안구 시각 문제가

PD에서 보고되었습니다 [2, 4].

PD의 시각적 결함은

전반적인 운동 기능에 영향을 미치고[5],

환각 발생의 위험 요인이 되며[6],

전반적인 삶의 질에 상당한 영향을 미칠 수 있습니다[2].

실제

파킨슨병 진단이 내려지기 몇 년 전의

전구기에 대한 인식이 높아지고 있으며,

이 단계에는 도파민뿐만 아니라

비도파민 관련 경로가 포함될 수 있습니다[7].

또한,

'파킨슨병 관련 위험 증후군'이라는 개념이 제안되었는데,

이는 위험군 환자가 질병에 걸리기 쉬운 유전적 요인을 가지고 있거나

조기에 비운동성 위험 증상을 보일 수 있습니다 [8].

따라서

운동 기능,

자율신경계 기능 장애,

신경심리 장애가 파킨슨병 초기에 발생할 수 있습니다[7, 9, 10].

이러한 변화 중 일부는

질병 초기에

중추 및 말초 도파민 신경전달물질 시스템의 퇴행을 반영할 수 있습니다[11];

도파민 탈신경화 시작과

운동 증상 발현 사이의 지연은

5~20년입니다[7].

PD의 초기 단계에서

개인을 감지할 수 있는 잠재적 바이오마커를 식별하여

조기 개입과 잠재적 신경 보호를 가능하게 할 수 있습니다 [10].

엄밀히 말하면

전구 질환은

PD가 확실히 진단되기 전에 존재하는 상태를 정의하므로

초기 임상 PD에 대한 연구는

전구 질환을 직접 평가하지는 않지만,

궁극적으로 이러한 특징이 전구 단계에 존재하는 것으로 나타날 수 있습니다 [12].

PD가 진행됨에 따라

인지 장애도 발생할 수 있으며,

미묘한 정신 기능 장애부터 명백한 치매까지 다양합니다 [13].

PD와 관련된 치매(PD 치매)는

특히 쇠약해지는 질환으로,

환자의 80%가 잠재적 위험에 처해 있습니다[14].

PD 치매의 위험은

환자 연령에 따라 증가하며,

기록된 사례의 90%가 70세 이상입니다[15].

새로 PD를 진단받은 환자를 대상으로 한

종단적 지역사회 기반 연구에서

환자의 10%가 진단 후 평균 3.5년 후에 치매가 발병했고

57%가 인지 장애의 증거를 보였으며,

전측 선조체 결손이 가장 흔했습니다 [16].

치매의 가장 중요한 예측 인자는

의미 유창성 테스트와

기하학적 도형 모방,

후피질 병리의 영향을 받고

비도파민 기능 장애와 관련이 있을 수 있는 과제였습니다 [16].

PD의 회백질 위축은

인지 장애의 정도에 따라 달라집니다 [17].

따라서

인지 장애가 거의 없는 PD 환자는

인지 장애가 없는 환자와 비교했을 때

위축 정도에 큰 차이가 나타나지 않습니다.

반면, 경도 인지 장애가 있는 PD 환자는

측두엽, 두정엽, 전두엽 피질뿐만 아니라

꼬리핵, 해마, 편도체, 미상핵에 영향을 미치는 제한적인 위축을 보입니다.

PD 치매에서는

해마상회, 시각 피질, 미상 회로의 회백질 부피 감소가 추가로 나타날 수 있습니다 [17].

최근에는

PD에 후각 결손이 있는 경우

PD 치매 발병 위험이 높아진다는 연구 결과가 발표되었지만[14],

아직 논란의 여지가 있습니다[18].

PD는

또한 밀접하게 관련된 운동 장애,

즉 '파킨슨 증후군'이라는 더 큰 그룹의 일원입니다.

이 그룹에는

진행성 핵상 마비(PSP) [19],

루이소체 치매(DLB) [20],

다계통 위축(MSA) [21],

피질 기저부 변성(CBD) [22] 등이 포함됩니다.

이 그룹 내에서 PD의 감별 진단은

특히 질병 초기에 어려울 수 있지만,

시각적 징후와 증상이 있는 경우

진단에 유용한 보조 자료가 될 수 있습니다[2].

이 글에서는

(1) 질병의 전구기에 특징적인 시각 증상이 있는지,

(2) PD 치매가 특정 시각 변화의 악화와 관련이 있는지,

(3) 시각 증상이 파킨슨병 증후군의 감별 진단에 도움이 될 수 있는지 등 세 가지 질문을 중심으로

PD의 안구 시각 증상을 검토합니다.

이러한

많은 시각적 변화의 원인이 될 수 있는

분자 및 신경전달물질 결핍에 대해서도 논의합니다.

MOLECULAR AND NEUROTRANSMITTER DEFICITS IN PD

Although dysfunction of the dopamine neurotransmitter system has long been associated with the pathophysiology of PD [2, 4] accumulating evidence suggests that PD is a multisystem degeneration [23]. Dopamine is an important neurotransmitter in the retina being present in amacrine cells along the inner border of the inner nuclear layer (INL) [24] (Fig. 1), and accumulated by interplexiform cells [25]. Two types of amacrine cells appear to be involved: (1) type 1 cells which send ascending processes to synapse with γ-aminobutyric acid (GABA) interplexiform cells in stratum 1 of the INL and (2) type 2 cells which have dendrites stratifying above those of the type 1 cells of the inner plexiform layer (IPL). Dopamine may be involved in the organisation of the ganglion cell and bipolar cell receptive fields and may modulate the physical activity of the photoreceptors [26]. In addition, dopamine is involved in the coupling of the horizontal and amacrine lateral system [27]. Thinning of the retinal nerve fibre layer (RNFL) has been recorded in PD [28] (Fig. 1). In particular, significant thinning of INL in parafoveal regions has been observed, especially in those patients exhibiting visual hallucinations but without overt signs of dementia [29].

PD의 분자 및 신경전달물질 결핍

도파민 신경전달물질 시스템의 기능 장애는

오랫동안 PD의 병태 생리와 관련이 있었지만 [2, 4]

축적된 증거는 PD가

다중 시스템 퇴행이라는 것을 시사합니다 [23].

multisystem degeneration

도파민은

망막에서 중요한 신경전달물질로

내핵층(INL)의 안쪽 경계를 따라 아마크린 세포에 존재하며[24](그림 1),

복합체 간 세포에 의해 축적됩니다[25].

Dopamine is an important neurotransmitter in the retina being present in amacrine cells along the inner border of the inner nuclear layer (INL)  [24] (Fig. 1), and accumulated by interplexiform cells [25]. Two types of amacrine cells appear to be involved: (1) type 1 cells which send ascending processes to synapse with γ-aminobutyric acid (GABA) interplexiform cells in stratum 1 of the INL and (2) type 2 cells which have dendrites stratifying above those of the type 1 cells of the inner plexiform layer (IPL).

두 가지 유형의 아마크린 세포가 관여하는 것으로 보입니다:

(1) INL의 1계층에서 γ-아미노부티르산(GABA) 간플렉서폼 세포와 시냅스를 형성하기 위해 상승 과정을 보내는 1형 세포와

(2) 내부플렉서폼 층(IPL)의 1형 세포 위에 수상돌기가 계층화되어 있는 2형 세포가 그것들입니다.

도파민은

신경절 세포와 양극성 세포 수용체의 조직에 관여할 수 있으며

광수용체의 물리적 활동을 조절할 수 있습니다 [26].

또한

도파민은 수평 및 아마크린 측면 시스템의 결합에 관여합니다 [27].

망막 신경 섬유층(RNFL)의 얇아짐이

PD에서 기록되었습니다 [28] (그림 1).

Thinning of the retinal nerve fibre layer (RNFL) has been recorded in PD [28] (Fig. 1).

특히,

시각적 환각을 보이지만

치매의 명백한 징후가 없는 환자에서

안와 주위 영역의 INL이 현저하게 얇아지는 것이 관찰되었습니다 [29].

Fig.1

Retinal image of a normal control subject using optical coherence tomography (OCT) showing the various functional layers: Fo = Location of fovea, NFL = Nerve fibre layer, GCL = Ganglion cell layer, IPL = Inner plexiform layer, INL = Inner nuclear layer, OPL = Outer plexiform layer, ONL = Outer nuclear layer, RPE = Retinal pigment epithelium, PR = Photoreceptor layer, N = Nasal direction, T = Temporal direction. A specific thinning of INL in the parafoveal region has been recorded in Parkinson’s disease (PD). (Image courtesy Dr R Heitmar, Aston University)

다양한 기능적 층을 보여주는 빛간섭단층촬영(OCT)을 사용한 정상 대조군의 망막 이미지: Fo = 중심와 위치, NFL = 신경섬유층, GCL = 신경절세포층, IPL = 내부 신경섬유층, INL = 내부 핵층, OPL = 외부 신경섬유층, ONL = 외부 핵층, RPE = 망막 색소 상피, PR = 광수용체층, N = 비강 방향, T = 시간적 방향. 

파킨슨병(PD)에서는 

안와 주위 영역에서 

INL의 특정 얇아짐이 기록되어 있습니다. (이미지 제공: 애스턴 대학교 R 하이트마 박사)

Two main dopamine pathways are present in the brain. First, the striatonigral pathway originates in the substantia nigra (cell group A9) and terminates in the striatum (caudate nucleus, putamen). Second, two pathways originate in the ventral tegmentum (cell groups A8, A10) and project to the nucleus accumbens and limbic system (mesolimbic pathway), and frontal cortex (mesocortical pathway). There are also dopamine pathways within the hypothalamus which transmit dopamine to the pituitary gland and four pathways connecting the ventral tegmentum to the amygdala, hippocampus, cingulate gyrus, and olfactory bulb. Significant dopamine activity is largely limited to frontal and limbic areas of cerebral cortex and there is significantly less activity in visual cortex [30]. Cerebral metabolic rates for glucose are also reduced by up to 23% in primary visual cortex (area V1) of PD patients [31]. Reductions in dopamine levels in basal ganglia and frontal cortex may also deplete levels in the superior colliculus and therefore could be a factor in the production of defective saccades [32]. Dopamine also has a peripheral role in sympathetic ganglia, visceral ganglia, and in artery walls. Hence, reductions in dopamine in some of these regions could be a factor contributing to eye movement problems and defects in pupil reactivity in PD.

There is increasing interest in the clinical effects of the degeneration of cholinergic basal forebrain and tegmental pedunculopontine complex projection in PD [33]. Across the spectrum of PD, whereas dopamine denervation is frequent in individuals with minimal or no cognitive change and increases with more severe cognitive impairment, cortical cholinergic denervation is a major degenerative process associated with cognitive decline [33]. Moreover, extra-nigral pathway and cholinergic deficits are particularly common in PD patients exhibiting ‘freezing of gait’ [34]. Nevertheless, cholinergic deficits in PD are variable and may aid selection of patients for targeted drug therapies [35].

Third, surviving neurons of the substantia nigra in PD often contain Lewy bodies (LB) which differ from other types of neurofibrillary pathology in that they contain abnormal aggregates of the protein α-synuclein [36]. α-Synuclein is a small pre-synaptic protein and the entire molecule undergoes a conformational change in PD resulting in the insoluble protein that forms a major component of the LB. The role of α-synuclein pathology in PD, however, is controversial. In a large post-mortem study of cases with α-synuclein pathology in the dorsal motor vagus, substantia nigra, and basal forebrain, only 32/106 cases had been diagnosed with a neurodegenerative disorder [37]. In addition, neither the distribution nor load of α-synuclein permitted dependable post-mortem diagnosis of extrapyramidal symptoms or cognitive impairment.

뇌에는

두 가지 주요 도파민 경로가 존재합니다.

첫째, 선조체 경로 striatonigral pathway 는

흑질(세포 그룹 A9)에서 시작하여

선조체(꼬리핵, 퍼타멘)에서 종결됩니다.

둘째, 두 개의 경로는

복측 선조체(세포 그룹 A8, A10)에서 시작하여

중핵과 변연계(중변연계 경로),

전두엽 피질(중피질 경로)로 뻗어 나갑니다.

또한

시상하부에는

뇌하수체에 도파민을 전달하는 도파민 경로가 있으며

복측 뇌량과 편도체, 해마, 미상회, 후각 전구를 연결하는 네 가지 경로가 있습니다.

https://en.wikipedia.org/wiki/Dopaminergic_pathways

중요한 도파민 활동은

대뇌 피질의 전두엽과 변연계 영역으로 크게 제한되며

시각 피질에서는 활동이 현저히 적습니다[30].

포도당에 대한 대뇌 대사율도

PD 환자의 일차 시각 피질(V1 영역)에서

최대 23%까지 감소합니다[31].

기저핵과 전두피질에서

도파민 수치가 감소하면

상대상회에서도 도파민 수치가 고갈되어

결함성 사카이드 생성의 요인이 될 수 있습니다 [32].

도파민은 또한

교감 신경절,

내장 신경절 및 동맥벽에서 말초적인 역할을 합니다.

따라서

이러한 영역 중 일부에서

도파민이 감소하면

PD에서 안구 운동 문제와 동공 반응성 결함을 유발하는 요인이 될 수 있습니다.

PD에서

콜린성 기저 전두엽과

분절성 안와돌기 복합체 투영의 퇴행이 미치는

임상적 영향에 대한 관심이 증가하고 있습니다 [33].

도파민 탈신경은

인지 변화가 미미하거나 없는 개인에서 빈번하게 발생하고

인지 장애가 심할수록 증가하는 반면,

피질 콜린성 탈신경은

인지 저하와 관련된 주요 퇴행성 과정입니다 [33].

또한,

흑질 외 경로와 콜린성 결손은

'보행 동결'을 보이는 PD 환자에서 특히 흔합니다[34].

그럼에도 불구하고

PD의 콜린성 결핍은

가변적이며 표적 약물 치료 대상 환자 선정에 도움이 될 수 있습니다 [35].

셋째,

PD에서 살아남은 흑질의 신경세포는

종종 루이체(LB)를 포함하는데,

이는 α-시누클레인 단백질의 비정상적인 응집체를 포함한다는 점에서

다른 유형의 신경섬유 병리와는 다릅니다 [36].

α-시누클레인은

작은 시냅스 전 단백질이며

전체 분자가 PD에서 형태 변화를 일으켜

불용성 단백질이 되어 LB의 주요 구성 요소를 형성합니다.

그러나

PD에서 α

-시누클레인 병리의 역할은 논란의 여지가 있습니다.

등운동 미주, 흑질 및 기저 전뇌에

α-시누클레인 병리가 있는 사례에 대한 대규모 사후 연구에서

32/106 사례만이 신경 퇴행성 장애로 진단되었습니다 [37].

또한

α-시누클레인의 분포나 부하는

피라미드 외 증상이나

인지 장애의 사후 진단을 신뢰할 수 있게 해주지 못했습니다.

Go to:

OCULO-VISUAL SYMPTOMS IN PD

The oculo-visual problems that may be present in prodromal PD, in PD generally, and most likely to be exacerbated in PD dementia are summarised in columns 2–4 of Table 1.

Table 1

Comparison of oculo-visual dysfunction in Parkinson’s disease (PD) and other parkinsonian syndromes

Disorder

Open in a separate window

Abbreviations: Disorders: PR = Prodromal phase of disease, PD = Parkinson’s disease without dementia, PD-Dem = Parkinson’s disease with dementia DLB = Dementia with Lewy bodies, PSP = Progressive supranuclear palsy, CBD = Corticobasal degeneration; MSA = Multiple system atrophy, Visual features: EM = Eye movements, EP = Evoked potential, ERG = Electroretinogram, VEP = Visual evoked potential; Symbols: Unaffected (–), Affected (+), Controversial (±). Superscripts: Ch = Chromatic VEP, f = Flash VEP, fa = Faces, on = Abnormal optokinetic nystagmus, r = rarely present Blanks indicate where limited available data to assess visual function. PD dementia data include only features where there is evidence suggesting exacerbation with developing cognitivedysfunction.

Colour vision

Colour vision dysfunction maybe a disease specific feature of PD [38–40] and has been suggested as a possible diagnostic sign [41]. Hence, using the Farnsworth-Munsell 100-hue test, PD patients frequently exhibit higher error scores that controls after age adjustment, the frequency of error scores often correlating with the severity of motor symptoms [42]. In addition, vision in PD may be blurred using coloured stimuli [43] with reduced perception of monochromatic contours especially for dark-green, light-blue, and dark-red stimuli [44]. Defective colour vision may also be an early sign of dopamine dysfunction in PD [40]. Hence, in 100 idiopathic PD patients, 27 of whom were expressing PD linked mutations, colour vision was consistently impaired [45]. However, other studied suggest that colour vision may not be consistently impaired in early PD [46]. Although no overall significant differences between PD and controls were present in the study, elevation of error scores exceeding the upper limit of normality occurred in three cases. Colour vision deficits may be more characteristic of disorders characterised by α-synuclein-immunoreactive pathology such as PD/DLB [47]. However the pathophysiology of colour discrimination deficits in PD is likely to be complex. Hence, cognitive impairment can make a major contribution to the degree of colour discrimination deficits in PD [48]. In addition, the effect of coloured lights on gait and freezing of gait have been investigated in PD, with in a pilot experiment, green light improving gait and attenuating freezing of gait better than red or no light [49].

Visual fields

Few studies of visual field defects have been carried out in PD and there is poor evidence for the consistent presence of such deficits [50]. However, there is controversy regarding whether there is increased frequency of glaucomatous visual field defects in PD [51]. In addition, visual fields were also investigated in patients undergoing posterior pallidotomy, a surgical procedure which risks damaging structures such as the optic tract [52]. Of 40 such patients, three had visual field defects which could have been attributable to the surgery, viz., contralateral superior quadrantanopias, associated in two patients with small paracentral scotomas.

Saccadic and smooth pursuit eye movements

Objective assessment of oculomotor function in PD is usually made by electro-oculography. Electro-oculography responses are often normal in PD patients when the eyes are in the primary position or when resting. Abnormal saccadic and smooth pursuit eye movements, however, are well established in PD and reported in about 75% of patients [53]. Both reaction times and the maximum saccadic velocity of horizontal gaze are slower in PD than controls [53]. Saccadic eye movements may exhibit hypometria, i.e., ‘under reaching of task’ [32] while smooth pursuit movements may be interrupted by small additional saccades [53]. In addition, the amplitude of saccadic eye movements is often increased in normal subjects when there is a change from externally cued saccades to self-paced saccades and this effect is often greater in PD [54]. In a study in which the delay of remembered (imagined) saccades was gradually increased in untreated PD, there was a marked hypometria of saccadic gain at all delays suggesting dysfunction of the striato-collicular inhibitory pathway resulting from dopamine deficiency in the basal ganglia [53]. In addition, spatial working memory was studied in relation to eye movements in which a sequence of four targets was memorised by the patient and then the eyes were moved to fixate the targets in their correct order. In PD, several discrete saccadic eye movements of reduced amplitude were necessary before reaching the final eye position and the patients also exhibited an increase in errors while remembering the target sequence.

Electro-oculography recordings have also been made before and after apomorphine treatment in early stage patients suggesting that smooth pursuit movements could be affected during the prodromal phase [57]. In addition, patients with PD often have difficulty in sustaining repetitive actions and hence, smooth pursuit movements exhibit a reduction in response magnitude and a progressive decline of response with stimulus repetition.

Stereopsis

Impairment of stereopsis (‘depth perception’) can be observed in PD associated with impaired VA and colour perception [58, 59], and has been attributable to pathology in extrastriate cortical areas [60]. Stereopsis is mediated by various neural pathways involving the thalamus and posterior parietal lobe, areas likely to be affected in PD and especially in PD dementia, as the pathology spreads to posterior parietal regions.

Nystagmus and convergence

Abnormal optokinetic nystagmus (‘train nystagmus’), an abnormal rhythmical movement of the eyes, induced when a patient looks at a moving object [53], and poor convergence, i.e., the ability of both eyes to fixate a common point [61], have both been reported in PD and are also important signs in PSP. Convergence can be associated with a relatively large outward deviation of the eye (exophoria), and the result is often double vision [62].

Eyelids

Eyelid problems in parkinsonian syndromes can seriously impair vision as a result of difficulties in opening the lids after voluntary closure (‘apraxia of eyelid opening’) [63]. Apraxia of eyelid opening can occur at the onset of disease [64] and the condition may worsen if the patient is given L-dopa as a possible treatment. The problem is likely to be attributable to a loss of the reciprocal relationship between the levator palpebrae and the pretarsal portion of the orbicularis oculi muscles, both of which contract together in PSP rather than exhibiting their normal opponent action. In addition, involuntary eyelid closure can occur after deep brain stimulation of the subthalamic nucleus in PD, implicating this region in pathophysiology [65].

A reduced frequency of blinking leading to a staring appearance is common in PD [60]. Reduced blink rates can also lead to an abnormal tear film, dry eye, and reduced vision. A characteristic ocular sign of PD is the blink reflex, elicited by a light tap above the bridge of the nose, successive taps in normal individuals producing less and less response as the reflex habituates [66]. In PD, the blink reflex may not disappear on repeated tapping. In addition, blink duration may be increased in PD and may be a consequence of the increasing loss of dopamine neurons [67]. The blink reflex is mediated by: (1) the nasociliary branch of the trigeminal nerves which senses the stimulus, (2) the temporal and zygomatic branches of the facial nerve which initiate a motor response, and (3) a number of nuclei in the pons. Hence, the pathophysiology of the blink reflex in PD is likely to be complex [68] with dopamine dysfunction in frontal lobes [69] and a reduction in the inhibitory effect of the nucleus reticularis giganto cellularis as possible contributory factors [70].

Pupil reactivity

Significantly larger pupil diameters, with unequal pupil sizes (anisocoria) after light adaptation, have been reported in PD [71], no such differences being apparent after dark adaptation. In addition, longer light reflex latencies and constriction times have been observed while contraction amplitudes may be reduced [66]. These results suggest autonomic imbalance in PD involving the parasympathetic system. Autonomic dysfunction can be an early manifestation of PD [72] and therefore, changes in pupil reaction could be present in the prodromal phase. In addition, the maximum contraction ability of the iris muscle measured in vitro is greater in PD than in controls suggesting that the muscle may have acquired adaptive sensitivity changes [73].

Contrast sensitivity

Patients with PD and PD dementia frequently complain of poor vision especially as the disease progresses [74, 75]. In addition, contrast sensitivity function (CSF) is affected in a proportion of PD patients [76, 77], performance at high or intermediate frequencies being the most common. In some individuals, a substantial decrease in CSF occurs with disease progression which could explain reports of poor vision in PD. Abnormalities in CSF could be related to dopamine dysfunction in the retina, but are often orientation specific, suggesting cortical involvement [78]. Treatment with L-dopa can improve CSF performance in PD close to that of controls while treatment with apomorphine significantly improves non-colour spatial CSF at all frequencies [79].

Motion detection

Decreased sensitivity to temporally changing stimuli may also occur in PD and is especially well demonstrated by studies of the auditory system. Hence, in psychophysical tests assessing auditory processing, bilateral subthalamic nucleus stimulation caused dysfunction in ability to track rapid fluctuations in sound intensity [80]. In addition, in motor tasks involving finger tapping, PD patients were impaired both in the motor task itself and in assessing its duration implicating pathology in basal ganglia and the thalamocortical connections involved in timing [81]. Subsequently, the substantia nigra was shown to be involved in temporal processing involving motor and perceptual tasks [82]. Hence, there could be deficits in the visual perception of rapidly moving stimuli in PD which could potentially cause problems in tracking fast moving targets.

Electroretinogram

The amplitude of the electroretinogram ‘b’ wave is reduced in PD under a variety of light conditions [83]. The amplitude of the ‘b’ wave may be an indicator of INL function and therefore, its reduction may reflect defects in visual processing involving dopamine neurons. The amplitude of the pattern response electroretinogram (PERG) to a checkerboard stimulus is also decreased in PD [83] and the latency of the P50 component delayed [84]. Subsequent studies have suggested that retinal dopamine depletion may result in attenuated electroretinogram responses to peak stimuli [85]. In addition, steady-state pattern PERG to sinusoidal gratings was studied over a range of spatial frequencies [86]. Aging affected responses at all spatial frequencies but the pattern of age-related loss was different in PD. In PD, a specific deficit at medium spatial frequencies was present accompanied by a distorted PERG spatial frequency response function. PERG is also sensitive to dopamine manipulation in the monkey retina [87]. In an experiment involving the use of a selective D2 antagonist, treatment affected the PERG to a sinusoidal vertical grating presented at four spatial frequencies [87]. Hence, dopamine appears to be involved in retinal processing and the D2 receptor to be necessary for spatial-temporal tuning of pattern vision. Subsequently it was shown that the two dopamine receptors D1 and D2 play different roles in retinal function and therefore affect vision differently in PD [88]. Hence, PERG could be useful both in eval‎uating retinal dopamine mechanisms and in monitoring dopamine therapies in PD.

Visual evoked potentials (VEP)

Visual evoked potentials (VEP) in response to coloured stimuli are affected in PD [89]. Hence, in some patients, amplitude is decreased and latency increased for all chromatic stimuli and especially for those using blue-yellow horizontal gratings [90]. Increased latency of the VEP P100 component to a checkerboard stimulus has also been reported in PD suggesting a delay in visual processing at one or more stages of the visual system [91–93]. As there is significantly less dopamine activity in visual cortex, these responses are likely to be related to other neurotransomitters such as the cholinergic system.

Complex visual functions

Perceptual abnormalities in PD may result from dopamine dysfunction in the retina (‘bottom-up’) or can be attributable to deficiencies in attention due to dysfunction of the striato-frontal system (‘top-down’) [94]. Hence, mild PD is associated with little perceptual abnormality, moderate PD with top-down abnormalities, and more severe PD with both types of abnormality, data which suggest retinal effects on perception occur later in the disease [94]. In addition, the presence of visuo-perceptual impairment could be an indication of developing PD dementia [13].

There are also prominent deficits in PD involving neuropsychological tests requiring self motivation and a demanding response from the patient [1]. Hence, PD patients may exhibit a variety of deficits in visuo-spatial orientation [95, 96] including difficulty in judging verticals and the position of body parts, and in carrying out a route-walking task. Visuo-spatial working memory also appears to be selectively impaired in early PD which probably reflects degeneration of the basal ganglia, the dorsal visual stream, and the frontal-prefrontal cortex [1]. In a problem solving task involving arranging coloured balls in pockets on a computer screen, PD patients made more errors than controls and also did not show any dissociation in the amount of time fixating the two halves of the display [97]. The results suggested difficulties in encoding and/or maintaining current goals during problem solving in PD.

Studies also suggest deficits in visuo-motor adaptation early in the disease [98]. Hence, in two tasks carried out over three days involving mirror reading and reversed vision using a prism, mirror reading time was increased after one day and there was significantly more slowing on the reversed vision task in early PD, neither effect being correlated with the Wechsler memory score of the patient [98]. In addition, motor adaptation to imposed visual rotation was significantly enhanced when tested days later after a sleep-dependent memory consolidation, PD patients and controls showing similar movements and adaptation to rotation [99]. After a few days, however, PD patients did not show this consolidation.

PD patients also show an impairment of orientation and motion discrimination [100], tasks most likely to involve the visual cortex. In addition, impairments in the ability to perceive and imagine faces have been reported in PD [101]. Medicated and non-medicated patients exhibit facial recognition problems but these deficits are most frequently present in the untreated group [102]. In addition, normal subjects contract their facial muscles while imaging faces, a process which is often impaired in PD.

Visual hallucinations

Visual hallucinations are a chronic complication of PD [103, 104] especially in patients treated with L-dopa and dopamine agonists and those diagnosed with PD dementia. In a large study of PD patients, hallucinations occurred in the previous three months in 40% of patients examined, being visual in 22% and auditory in 10% of patients [103]. Patients with minor hallucinations had higher depression scores than those without. A number of factors were the best predictors of hallucinations, viz., a severe cognitive defect, daytime somnolence, longer duration of disease, poor vision, and reduced activity in primary visual cortex [31]. Hallucinations in PD are often complex with flickering lights, and illusionary misconceptions often preceding the most common manifestation, viz., stereotypical colourful images [104].

Go to:

IS VISION AFFECTED IN THE PRODROMAL STAGE?

A number of oculo-visual features observed in early PD could be present in the prodromal phase of PD (Table 1). First, autonomic system dysfunction is well documented in early PD [72] and could affect pupil reactivity, and is a feature requiring further investigation. Second, electro-oculographic recordings have been made before and after apomorphine treatment confirm‎ing that smooth pursuit movements can be affected during the initial stages [57]. Third, deficits in colour vision may occur early in the disease [40]. Fourth, deficits in visuo-motor adaptation may occur during the early stages [98]. Fifth, in PD cases in which idiopathic rapid eye movement (REM) sleep behaviour disorder is accompanied by abnormal stereopsis, postural instability may be an additional feature [105]. The presence of any of these features in undiagnosed individuals may raise a concern of possible PD. Since early diagnosis may enable intervention and possible neuroprotection [10], further visual studies of the early stage PD are urgently needed.

Go to:

IS VISION SPECIFICALLY AFFECTED IN PD DEMENTIA?

Many of the oculo-visual features present in early and middle stage PD will become more severe if the patient develops PD dementia. However, some features appear to be particularly exacerbated in PD dementia including deficits in colour vision [47] and changes in pupillary function [73, 106] (Table 1). In addition, there are visual features which may be particularly characteristic of PD dementia. First, prominent visual hallucinations are significantly more frequent in PD dementia than PD [107–110]. Second, severe eye movement problems are more likely to be present in PD dementia and to become more extensive with declining cognitive function [111, 112]. Third, defects in visuospatial orientation are likely to be greater in PD dementia especially when associated with greater cortical atrophy [113]. Many additional visual features, already detected in PD, are likely to be present in a more severe form in PD dementia.

Go to:

CAN OCULO-VISUAL SYMPTOMS AID DIFFERENTIAL DIAGNOSIS?

Many of the parkinsonian syndromes have overlapping clinical features (Table 1) making differential diagnosis difficult. In patients with unclassifiable or with indeterminate parkinsonian symptoms, however, the presence of visual hallucinations is an important symptom which may indicate underlying LB pathology, i.e., supporting a diagnosis of PD/DLB rather than PSP/CBD or MSA [109].

Dementia with Lewy bodies (DLB)

A recent review of PD carried out by the ‘International Parkinson’s disease and Movement Disorders Societies’ has identified considerable heterogeneity within the disease, has questioned the role of classic α-synuclein pathology in pathophysiology, and considers whether PD and DLB should continue to be regarded as distinct disorders [114]. Separating PD from DLB was thought to be important because patients with visual hallucinations may be treated with antipsychotic drugs, regarded as a hazardous treatment in DLB [115]. In addition, DLB patients were thought to exhibit fewer tremors, more asymmetry of motor symptoms, more falls, and respond less well to dopamine treatment than PD [110]. DLB and PD patients, however, exhibit similarities on a variety of saccadic eye movement tasks. A newly developed portable saccadometer has been used to compare saccadic latency distribution in several parkinsonian syndromes [116] suggesting that a combination of saccadic parameters could discriminate between PD and DLB better than any single parameter. Although there are similarities in general cognitive performance in PD and DLB there may also be subtle differences. For example, deficits in orientation, ‘trail-making’, and reading the names of colours (‘Stroop test’) suggest DLB rather than PD [117]. Visual perception tasks (visual discrimination, space-motion and object-form recognition), however, are usually equally impaired in DLB and PD, especially in patients with visual hallucinations [111]. Cognitive/psychiatric symptoms including overt dementia are generally less frequent in PD than in DLB [118]. However, it is likely that these differences reflect heterogeneity within PD or the presence of distinct disease subtypes of PD.

Progressive supranuclear palsy (PSP) and cortico-basal degeneration (CBD)

PSP and CBD are both four-repeat (4R) tau diseases exhibiting considerable similarities and overlap [19, 22]. Distinguishing PD from PSP can be especially difficult early in the disease. Atypical features of PSP include slowing of upward saccades, moderate slowing of downward saccades, the presence of a full range of voluntary vertical eye movements, a curved trajectory of oblique saccades, and absence of square-wave jerks [119]. Hence, particularly useful in separating PSP from PD is the presence in the former of vertical supranuclear gaze palsy, fixation instability, lid retraction, blepharospasm, and apraxia of eyelid opening and closing [120]. Downgaze palsy is probably the most useful diagnostic clinical symptom of PSP [121]. Deficits in colour vision appear to be more important in PD and directly related to the dopamine system. However, in untreated early PD, no consistent deficits in colour vision were demonstrated making this alone an unreliable indicator of PD [46].

By contrast, typical oculo-visual features of CBD include increased latency of saccadic eye movements [122–124], impaired smooth pursuit movements [122], and visuo-spatial dysfunction especially involving object-based tasks [125]. Less typical features include vertical gaze palsy, visual hallucinations, sleep disturbance, and an impaired ERG. It is also possible that visuospatial deficits are more prominent in CBD, a mixed cortical/subcortical dementia, than in PD dementia.

Multiple system atrophy (MSA)

Anderson et al. [126] suggest several features suggestive of MSA including excessive square-wave jerks, mild to moderate hypometria of saccades, impaired vestibulo-ocular reflex (VOR), and the presence of nystagmus. In addition, visual hallucinations, unrelated to medication, are rare in MSA compared with PD and their presence can often exclude MSA as a possible diagnosis [127]. In addition, there is greater retinal pathology in PD, which results in significant defects in dynamic CSF and in the early components of the VEP, which are not likely to be present in MSA. Moreover, the colour VEP is affected in PD but not in MSA [128]. Nevertheless, where defects in the VEP occur in MSA, they are more likely to involve more complex event-related potentials and components such as the P300 [129, 130]. A feature which may be useful in separating PD and MSA is an ability to fixate an object, which is abnormal in a significant proportion of patients with MSA but less so in PD [131]. In addition, eye movements recorded during sinusoidal tracking by video-oculography show that in MSA, saccades correct for position error (‘catch-up saccades’) while in PD, saccades are directed towards future target positions (‘anticipatory saccades’) [132].

In conclusion, PD can affect visual acuity, CSF, colour discrimination, pupil reactivity, eye movement, motion perception, and visual processing speeds. Disturbances of visuo-spatial orientation, facial recognition problems, and chronic visual hallucinations may also be present. Possible prodromal features of PD include autonomic system dysfunction which could affect pupil reactivity, abnormal colour vision and stereopsis, the latter associated with postural instability, and abnormal smooth pursuit eye movement function. PD dementia is associated with the exacerbation of many of the oculo-visual problems present in PD generally but those involving eye movements, visuo-spatial function and visual hallucinations appear most characteristic. Useful diagnostic features in differentiating the parkinsonian symptoms are the presence/absence of visual hallucinations, visuo-spatial problems, and variation in saccadic eye movementdysfunction.

Go to:

REFERENCES

1. Antal A, Bandini P, Keri S, Bodis-Wollner I. Visuo-cognitive dysfunctions in Parkinson’s disease. Clin Neurosci. 1998;5:147–152. [PubMed] [Google Scholar]

2. Armstrong RA. Visual signs and symptoms of Parkinson’s disease. Clin Exp Optom. 2008;91:129–138. [PubMed] [Google Scholar]

3. Earley CJ. Restless legs syndrome. New Eng J Med. 2003;348:2103–2109. [PubMed] [Google Scholar]

4. Armstrong RA. Parkinson’s disease and the eye. Ophthalmic Physiol Opt. 1997;17:S9–S16. [PubMed] [Google Scholar]

5. Diederich NJ, Raman R, Leurgans S, Goetz CG. Progressive worsening of spatial and chromatic processing deficits in Parkinson’s disease. Arch Neurol. 2002;59:1249–1252. [PubMed] [Google Scholar]

6. Matsui H, Udaka F, Tamura A, Oda M, Kubori T, Nishinaka K, Kameyama M. Impaired visual acuity as a risk factor for visual hallucinations in Parkinsons’s disease. J Geriatr Psychiatry Neurol. 2006;19:36–40. [PubMed] [Google Scholar]

7. Meissner WG. When does Parkinson’s disease begin? From prodromal disease to motor signs. Rev Neurol. 2012;168:809–814. [PubMed] [Google Scholar]

8. Stern MB, Siderowf A. Parkinson’s at risk syndrome: Can Parkinson’s disease be predicted? Mov Disord. 2010;25:S89–S93. [PubMed] [Google Scholar]

9. Schrag A, Horsfall L, Walters K, Noyce A, Petersen I. Prediagnostic presentations of Parkinson’s disease in primary care: A case-control study. Lancet Neurol. 2015;14:57–64. [PubMed] [Google Scholar]

10. Goldman JG, Postuma R. Premotor and non-motor features of Parkinson’s disease. Curr Opin Neurol. 2014;27:434–441. [PMC free article] [PubMed] [Google Scholar]

11. Rolheiser TM, Fulton HG, Good KP, Fisk JD, McKelvey JR, Scherfier C, Khan NM, Leslie RA, Robertson HA. Diffusion tensor imaging and olfactory identification testing in early-stage Parkinson’s disease. J Neurol. 2011;258:1254–1260. [PubMed] [Google Scholar]

12. Berg D, Lang AE, Postuma RB, Maetzler W, Deuschi G, Gasser T, Siderowf A, Schapira AH, Oertal W, Obeso OA, Olanow CW, Poewe W, Stern M. Changing the research criteria for the diagnosis of Parkinson’s disease: Obstacles and opportunities. Lancet Neurol. 2013;12:514–524. [PubMed] [Google Scholar]

13. Braak H, Rub U, Del Tredici K. Cognitive changes in sporadic Parkinson disease- a cliniconeuropathological correlation. Nervenheilkunde. 2005;24:129–136. [Google Scholar]

14. Baba T, Kikuchi A, Hirayama K, Nishio Y, Hosokai Y, Kanno S, Hasegawa T, Sugeno N, Konno M, Suzuki K, Takahashi S, Fukuda H, Aoki M, Itoyama Y, Mori E, Tajida A. Severe olfactory dysfunction is a prodromal symptom of dementia associated with Parkinson’s disease: A 3-year longitudinal study. Brain. 2012;135:161–169. [PubMed] [Google Scholar]

15. Rana AQ, Yousuf MS, Naz S, Qa’aty Preval‎ence and relation to dementia to various factors in Parkinson disease. Psychiatry Clin Neurosci. 2012;66:64–68. [PubMed] [Google Scholar]

16. Williams-Gray CH, Foltynie T, Brayne CEG, Robbins TW, Barker RA. Evolution of cognitive dysfunction in an incident Parkinson’s disease cohort. Brain. 2007;130:1787–1798. [PubMed] [Google Scholar]

17. Melzer TR, Watts R, MacAskill MR, Pitcher TL, Livingston L, Keenan RJ, Dalrymple-Alford JC, Anderson TJ. Grey matter atrophy in cognitively impaired Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2012;83:188–194. [PubMed] [Google Scholar]

18. Anang JBM, Gagnon JF, Bertrand JA, Romenets SR, Latreille V, Panisset M, Montplaisir J, Postuma RB. Predictors of dementia in Parkinson’s disease: A prospective study. Neurology. 2014;83:1253–1260. [PMC free article] [PubMed] [Google Scholar]

19. Armstrong RA. Visual signs and symptoms of progressive supranuclear palsy. Clin Exp Optom. 2011;95:150–160. [PubMed] [Google Scholar]

20. Armstrong RA. Visual signs and symptoms of dementia with Lewy bodies. Clin Exp Optom. 2012;94:621–630. [PubMed] [Google Scholar]

21. Armstrong RA. Visual signs and symptoms of multiple system atrophy. Clin Exp Optom. 2014;97:483–491. [PubMed] [Google Scholar]

22. Armstrong RA. Corticobas